Skip to main content
Sumitomo Pharma Co., Ltd. logo

Sumitomo Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4506 ISIN · JP3495000006 LEI · 529900D60UKVYLJ2OJ79 T Manufacturing
Open in API
Filings indexed 94 across all filing types
Latest filing 2024-10-30 Regulatory Filings
Country JP Japan
Listing T 4506

About Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Sumitomo Pharma Co., Ltd. is a research and development-driven pharmaceutical company focused on creating innovative pharmaceuticals and healthcare solutions. The company's primary therapeutic areas are Psychiatry & Neurology and Oncology, with additional activities in diabetes, rare diseases, and women's health. A key aspect of its R&D strategy is the integration of established expertise in small molecule drug discovery with pioneering modalities such as regenerative medicine and cell therapy. The company's mission is to translate scientific innovation into real-world solutions to contribute to the betterment of healthcare and fuller lives for people worldwide, with a strategic business focus on Japan and the United States.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 100% confidence The document is a Japanese regulatory filing, indicated by headers like "【提出書類】 臨時報告書" (Filing Document: Extraordinary Report) and references to the Financial Instruments and Exchange Act ("金融商品取引法"). The content explicitly states the reason for filing is a significant event affecting the financial condition, specifically reporting a foreign exchange loss ("為替差損") of 21,479 million yen recognized in the interim consolidated financial statements for the fiscal year ending March 2025. This structure—a formal report filed outside the regular annual/quarterly cycle due to a significant, unexpected event—is characteristic of an extraordinary report or a material event disclosure. Given the provided options, this type of material event disclosure, which is not a standard 10-K, IR, or ER, fits best under the general category for miscellaneous regulatory filings that report significant, non-scheduled events. While it details financial impact, it is not the full Interim Report (IR) or Earnings Release (ER), but rather a specific notification of a material event. Therefore, the most appropriate classification is Regulatory Filings (RNS) as a catch-all for specific, non-standard regulatory disclosures not covered by other codes, or potentially a general disclosure related to financial status changes. Since it is a formal, specific regulatory filing reporting a material financial event, RNS is the best fit among the choices for a non-standard disclosure.
2024-10-30 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau ('関東財務局長'). The submission date is July 31, 2024. Section 1 explicitly states the reason for filing is due to an event significantly impacting the financial condition, operating results, and cash flow, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. Section 2 details the event: recording a foreign exchange gain of 21,528 million yen in the first quarter of the fiscal year ending March 2025 due to foreign currency-denominated liabilities held by overseas subsidiaries. This structure—a formal, unscheduled filing detailing a significant, non-periodic financial event (like a large FX gain)—is characteristic of a Japanese regulatory filing that doesn't fit the standard periodic reports (10-K, IR). Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for miscellaneous, mandatory regulatory disclosures that aren't specifically defined elsewhere (like DIRS, DIV, or CAP). It is not an Earnings Release (ER) as it is an extraordinary event filing, not a standard quarterly report announcement.
2024-07-31 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (584 characters) and appears to be a confirmation document ('確認書') submitted to the Kanto Local Finance Bureau Director ('関東財務局長') regarding the appropriateness of the contents of a correction report for the Annual Securities Report ('有価証券報告書の訂正報告書'). The key elements are the confirmation of the contents of a filing correction and the reference to the Financial Instruments and Exchange Act. Since this is a formal confirmation related to a statutory filing (likely a 10-K correction, given the context of '有価証券報告書'), and it is not the full report itself, it fits best under the general 'Regulatory Filings' category (RNS) as a specific administrative confirmation document that doesn't match the other detailed categories like ER, IR, or 10-K directly, although it is closely related to the 10-K process. Given the nature of confirming the accuracy of a statutory filing, RNS is the most appropriate fallback for this administrative confirmation. FY 2024
2024-07-03 Japanese
訂正有価証券報告書－第204期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. The header explicitly identifies it as a 'Securities Report' (有価証券報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法第24条第１項) for the fiscal year ending March 31, 2024. It contains extensive XBRL metadata and financial reporting structures, confirming it is the full annual report rather than an announcement. FY 2024
2024-07-03 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted following the resolution of matters at the Annual General Meeting ('当社第204期定時株主総会において、決議事項が決議されました'). Section 2 details the voting results for the election of directors ('取締役８名選任の件') at the meeting held on June 25, 2024. This content—reporting the official results of shareholder votes from a general meeting—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the specific purpose is reporting the *results* of the vote, not providing the meeting materials (AGM-R) or proxy information (PSI).
2024-06-26 Japanese
内部統制報告書－第204期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document contains a header section explicitly stating the filing type as "内部統制報告書" (Internal Control Report) and references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法). It details the scope, standard date (March 31, 2024), and procedures for evaluating internal controls over financial reporting, concluding that the internal controls are effective. This structure and content strongly align with the requirements for an internal control report, which is a mandatory disclosure in Japan, often filed alongside the Annual Report (10-K equivalent) or as a standalone document. Given the specific focus on internal control assessment, it is best classified as an Audit Report / Information (AR), as it deals with the assessment of controls and financial reporting integrity, distinct from the full 10-K or a simple earnings release. While 'AR' definition mentions 'Audit Report / Information' and 'stress tests', in the context of Japanese filings, the Internal Control Report (J-SOX report) is a critical assurance document related to financial reporting integrity, making AR the closest fit among the provided options, as it is not a 10-K, ER, or IR.
2024-06-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.